Business Context and Reporting Period
This Form 8-K filing by Dermata Therapeutics, Inc. (DRMA) is dated May 14, 2025. The report addresses the company's compliance status with The Nasdaq Capital Market listing requirements, specifically regarding Stockholder's Equity and Minimum Bid Price.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance status rather than financial performance metrics.
Material Changes and Listing Status
- Stockholder's Equity: The company previously received notice on March 25, 2025, of non-compliance with the minimum stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)). As of May 14, 2025, the company has regained compliance, and this matter is closed.
- Minimum Bid Price: On May 14, 2025, the company received notice of non-compliance with the $1.00 Minimum Bid Price requirement (Nasdaq Listing Rule 5550(a)(2)).
- Delisting Risk: Due to a reverse stock split implemented within the prior year, the company's securities are subject to delisting and suspension at the opening of business on May 23, 2025, unless a hearing is requested.
Outlook, Risks, and Management Commentary
Management plans to request a hearing before the Nasdaq Hearings Panel by May 21, 2025. This request is intended to stay any suspension or delisting action pending the conclusion of the hearing process. The filing explicitly states there is no assurance that the compliance plan will be accepted or that the company will successfully maintain its listing. The company warns that failure to regain compliance or satisfy other requirements could result in delisting.
Investor Verification Checklist
- Confirm the filing date of the hearing request with the Nasdaq Hearings Panel (deadline: May 21, 2025).
- Monitor the outcome of the hearing regarding the Minimum Bid Price requirement.
- Verify the current trading price of DRMA to assess the likelihood of regaining the $1.00 minimum bid price.
- Review the company's most recent Form 10-K for detailed risk factors and financial position.